A Phase 1/2 Trial of BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma (Novartis Study Number CBKM120ZUS21T)
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Buparlisib (Primary) ; Vemurafenib
- Indications Malignant melanoma
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 15 Jun 2012 Planned End Date added to 1 Jul 2015 as reported by ClinicalTrials.gov.
- 15 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.